

YAYINLAR
MAKALELER & KİTAP BÖLÜMLERİ

2005

1. **Baran Y***, Gündüz U, Ural AU. Expression of multidrug resistance (MDR1) gene in human promyelocytic leukemia cell line selected with vincristine. Turkish Journal of Cancer, **2005**; 35(2): 88-92.

2. Önalın G*, Selam B, **Baran Y**, Cincik M, Onalan R, Gündüz U, Ural AU, Pabuççu R. Serum and follicular fluid levels of soluble Fas, soluble Fas ligand and apoptosis of luteinized granulosa cells in PCOS patients undergoing IVF. Human Reproduction, **2005**; 20(9): 2391-2395.

2006

3. **Baran Y***, Gunduz U, Ural AU. Cross-resistance to cytosine arabinoside in human acute myeloid leukemia cells selected for resistance to vincristine. Experimental Oncology, **2006**; 28(2): 163-165.

2007

4. Gorduysus M*, Avcu N, Gorduysus O, Pekel A, **Baran Y**, Avcu F, Ural AU. Cytotoxic Effects of Four Different Endodontic Materials in Human Periodontal Ligament Fibroblasts. Journal of Endodontics, **2007**; 33(12): 1450-1454.

5. Ural AU*, Avcu F, **Baran Y**. Rates of myocardial infarction and coronary artery disease and risk factors in patients treated with radiation therapy for early-stage breast cancer. Cancer, **2007**; 110(2): 469-470.

6. **Baran Y***, Gunduz U. Kronik Miyelositer Lösemi Genetiđi (Genetics of chronic myeloid leukemia). Journal of Turkish Internal Medicine, **2007**; 3(2): 50-55

7. **Baran Y***, Gur B, Kaya P, Ural AU, Avcu F, Gunduz U. Upregulation of multidrug resistance genes in doxorubicin resistant human acute myelogeneous leukemia cells and reversal of the resistance. Hematology, **2007**; 12(6): 511-517.

8. **Baran Y***, Ural AU, Gunduz U. Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells. Hematology, **2007**; 12(6): 497-503.

9. **Baran Y**, Salas A, Senkal CE, Gunduz U, Bielawski J, Obeid LM, Ogretmen B*. Alterations of Ceramide/Sphingosine 1-Phosphate Rheostat Involved in the Regulation of Resistance to

Imatinib-induced Apoptosis in K562 Human Chronic Myeloid Leukemia Cells. *Journal of Biological Chemistry*, **2007**; 282(15): 10922-10934.

2008

10. Baran Y*, Ural AU, Avcu F, Sarper M, Elçi P, Pekel A. Optimization of Transfection of Green Fluorescent Protein in Pursuing Mesenchymal Stem Cells, *In Vivo*. *Turkish Journal of Hematology*, **2008**; 25(4): 172-175.

11. Ural AU*, Avcu F, **Baran Y**. Bisphosphonate treatment and radiotherapy in metastatic breast cancer. *Medical Oncology*, **2008**; 25(3): 350-355.

2009

12. Abaan DO, Mutlu PK, **Baran Y**, Atalay MC, Gunduz U*. Multidrug Resistance Mediated by MRP1 Gene Overexpression in Breast Cancer Patients. *Cancer Investigation*, **2009**; 27(2): 201-205.

13. Karabulut B, Erten C, Gul MK, Cengiz E, Karaca B, Kucukzeybek Y, Gorumlu G, Atmaca H, Uzunoglu S, Sanli Ua, **Baran Y**, Uslu R*. Docetaxel/Zoledronic Acid Combination Triggers Apoptosis Synergistically Through Downregulating Antiapoptotic Bcl-2 Protein Level In Hormone-Refractory Prostate Cancer Cells. *Cell Biology International*, **2009**; 33(2): 239-246.

14. Gucluler G, **Baran Y***. Docetaxel Enhances the Cytotoxic Effects of Imatinib on Philadelphia Positive Human Chronic Myeloid Leukemia Cells. *Hematology*, **2009**; 14(3): 139-144.

15. Baran Y*, Oztekin C, Bassoy EY. Inhibition of Proteasome by Bortezomib Increased Chemosensitivity of BCR/ABL Positive Human K562 Chronic Myeloid Leukemia Cells to Imatinib. *Health*, **2009**; 1(4): 320-324.

2010

16. Ekiz A, Can G, Gunduz U, **Baran Y***. Nilotinib significantly induces apoptosis in imatinib-resistant K562 cells with wild-type BCR-ABL, as effectively as in parental sensitive counterparts. *Hematology*, **2010**; 15(1): 33-38.

17. Goktas S, **Baran Y**, Ural AU, Yazici S*, Aydur E, Basal S, Avcu F, Pekel A, Dirican B, Beyzadeoglu M. Proteasome Inhibitor Bortezomib Increases Radiation Sensitivity in Androgen Independent Human Prostate Cancer Cells. *Urology*, **2010**; 75(4): 793-798.

18. Baran Y*, Oztekin C, Bassoy EY. Combination of fludarabine and imatinib induces apoptosis synergistically through loss of mitochondrial membrane potential and increases in caspase-3 enzyme activity in human K562 chronic myeloid leukemia cells. *Cancer Investigation*, **2010**; 28(6): 623-628.

19. Ekiz HA, **Baran Y***. Therapeutic Applications of Bioactive Sphingolipids in Hematological Malignancies. *International Journal of Cancer*, **2010**; 127(7): 1497-506.

20. Kosova B, Tezcanli B, Ekiz HA, Cakir Z, Selvi N, Dalmizrak A, Kartal M, Gunduz U, **Baran Y***. Suppression of STAT5A increases chemotherapeutic sensitivity in imatinib-resistant and imatinib-sensitive K562 cells. *Leukemia and Lymphoma*, **2010**; 51(10): 1895-901.

2011

21. Cakir Z, Saydam G, Sahin F, **Baran Y***. The Roles Of Bioactive Sphingolipids In Resveratrol-Induced Apoptosis In HL60 Acute Myeloid Leukemia Cells. *Journal Of Cancer Research And Clinical Oncology*, **2011**; 137: 279–286.

22. Avci CB, Gunduz C, **Baran Y**, Sahin F, Yilmaz S, Dogan ZO, Saydam G*. Caffeic Acid Phenethyl Esther Triggers Apoptosis Through Induction of Loss of Mitochondrial Membrane Potential in CCRF-CEM. *Journal of Cancer Research and Clinical Oncology*, **2011**; 137: 41-47.

23. Can G, Ekiz A, **Baran Y***. Imatinib induces autophagy through BECLIN-1 and ATG5 genes in chronic myeloid leukemia cells. *Hematology*, **2011**; 16(2): 95-99.

24. Kartal M, Saydam G, Sahin, **Baran Y***. Resveratrol triggers apoptosis through regulating ceramide metabolizing genes in human K562 chronic myeloid leukemia cells. *Nutrition and Cancer; An International Journal*, **2011**; 63(4): 637-644.

25. Sanli MG, Turan T, Ekiz HA, **Baran Y***. The importance of protein profiling in the diagnosis and treatment of hematologic malignancies. *Turkish Journal of Hematology*, **2011**; 28: 1-14.

26. Mutlu P, **Baran Y**, Ural AU, Avcu F, Dirican B, Beyzadeoglu M, Gündüz U*. Effect Of Cobalt-60 (Γ Radiation) On Multidrug Resistant Multiple Myeloma Cell Lines. *Cell Biology International*, **2011**; 35(7): 721-5.

27. Salas A, Ponnusamy S, Senkal CE, Meyers MA, Selvam SP, Saddoughi SA, Apohan E, Sentelle RD, Smith C, Gault CR, Obeid LM, El-Shewy HM, Oaks J, Ramasamy S, Marcucci G, **Baran Y**, Mahajan S, Fernandes D, Stuart RK, Perrotti D, Ogretmen B*. : Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A. *Blood*, **2011**; 117(22): 5941-5952.

28. Ekiz HA, **Baran Y***. Bioactive Sphingolipids in Response to Chemotherapy: A Scope on Leukemias. *Anti-Cancer Agents in Medicinal Chemistry*, **2011**; 11: 385-397.

29. Camgoz A, Gencer EB, Ural AU, Avcu F, **Baran Y***. Roles of ceramide synthase and ceramide clearence genes in nilotinib-induced cell death in chronic myeloid leukemia cells. *Leukemia and Lymphoma*, **2011**; 52(8): 1574-84.

- 30.** Firinci F*, Karaman M, **Baran Y**, Bagriyanik A, Ayyildiz ZA, Kiray M, Kozanoglu I, Yilmaz O, Uzuner N, Karaman O. Mesenchymal Stem Cells Ameliorate The Histopathological Changes in a Murine Model of Chronic Asthma. *International Immunopharmacology*, **2011**; 11(8): 1120-1126.
- 31.** Avcı ÇB, Yılmaz S, Dogan ZO, Saydam G, Dodurga Y, Ekiz HA, Kartal M, Sahin F, **Baran Y***, Gunduz C. Quercetin-induced Apoptosis involves increased HTERT enzyme activity of Leukemic Cells. *Hematology*, **2011**; 16(5): 303-307.
- 32.** **Baran Y***, Bielawski J, Gunduz U, Ogretmen B. Targeting glucosylceramide synthase sensitizes imatinib-resistant chronic myeloid leukemia cells via endogenous ceramide accumulation. *Journal of Cancer Research and Clinical Oncology*, **2011**; 137(10): 1535-1544.
- 33.** Gencer EB, Ural AU, Avcu F, **Baran Y***. A novel mechanism of dasatinib-induced apoptosis in chronic myeloid leukemia; ceramide synthase and ceramide clearance genes. *Annals of Hematology*, **2011**; 90(11): 1265-1275.
- 34.** Avcu F, Avcu N*, Er N, Kansu Ö, **Baran Y**, Pekel A, Ural AU. The Cytotoxic and Apoptotic-Necrotic Effects of Whitening Materials on Human Gingival Fibroblasts. *Clinical Dentistry and Research*, **2011**; 35(1): 3-11.
- 35.** **Baran Y**, Zencir S, Çakır Z, Öztürk E, Topçu Z*. Imatinib-induced apoptosis; A possible link to topoisomerase enzyme inhibition. *Journal of Clinical Pharmacy and Therapeutics*, **2011**; 36(6): 673-679.
- 36.** Adan A, Kartal M, **Baran Y***. Meme Kanserinin Moleküler Biyolojisi (Molecular Biology of Breast Cancer). **2011**, Kitap Bölümü, Meme Kanserine Moleküler Yaklaşım Molecular Approaches to Breast Cancer, ISBN: 978-975-483-928-9.
- 37.** **Baran Y***. Hücrenin Kritik Kararı; Yaşamak ya da Ölmek. **2011**, Kitap Bölümü, I. Hücre Ölümü Araştırma Teknikleri Teorik Kursu, ISBN: 978-975-441-349-6.
- 38.** **Baran Y***. Hücre Ölümü Çalışmalarında Gen Aktarım Teknikleri. **2011**, Kitap Bölümü, I. Hücre Ölümü Araştırma Teknikleri Teorik Kursu, ISBN: 978-975-441-349-6.
- 39.** Gucluler G, Piskin O, **Baran Y***. The roles of antiapoptotic sphingosine kinase-1 and glucosylceramide genes in drug induced cell death of MCF-7 breast cancer cells. *J BUON*, **2011**; 16(4): 646-651.
- 2012**
- 40.** Ekiz HA, Can G, **Baran Y***. Role of autophagy in the progression and suppression of leukemias. *Critical Reviews in Hematology/Oncology*, **2012**; 81(3): 275-285.

41. Bassoy EY and **Baran Y***. Bioactive Sphingolipids in Docetaxel-Induced Apoptosis in Human Prostate Cancer Cells. *Biomedicine And Pharmacotherapy*, **2012**; 66(2): 103-110.

42. Purclutepe O, Iskender G, Kiper HD, Tezcanli B, Selvi N, Avci CB, Kosova B, Sahin F, **Baran Y***, Saydam G. Enalapril-Induced Apoptosis of Acute Promyelocytic Leukemia Cells Involves STAT5A. *Anticancer Research*, **2012**; 32: 2885-2894.

43. Ceylan C, Camgoz A, **Baran Y***. Macromolecular changes in nilotinib resistant K562 cells; an in vitro study by Fourier transform infrared spectroscopy. *Technology in Cancer Research & Treatment*, **2012**; 11(4): 333-344.

44. Can G, Cakir Z, Kartal M, Gunduz U, **Baran Y***. Apoptotic Effects of Resveratrol, a Grape Polyphenol, on Imatinib Sensitive and Resistant K562 Chronic Myeloid Leukemia Cells. *Anticancer Research*, **2012**; 32(7): 2673-8.

45. **Baran Y***, Saydam G. Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic myeloid leukemia. *Journal of Blood Medicine*, **2012**; 3: 139–150.

46. Bozcuk H, Abali H, Coskun S, Aydinler A, Çinkaya A, Demirkazık A, Özet A, Yolcu A, Balkan A, Çavdar A, Kefeli AÜ, Uluç BO, Atasoy B, Demirkan B, Yalçın B, Eroğlu C, Yalman D, Kılıç D, Tunalı D, Fırat D, Seber E, Üçgül Çavuşoğlu E, Ulukaya E, Kaytan Sağlam E, Tezcanlı E, Eryılmaz E, Dinçbaş FÖ, Telli F, Yumuk F, Başaran G, Çağlar HB, Sönmez H, Yılmaz H, Engin H, Helvacı K, Sönmez K, Koral L, Artaç M, Fuat Eren M, Koçar M, Beyzadeoğlu M, Akın M, Benekli M, Cengiz M, Erman M, Yıldız M, Doğan M, Balkan M, Eraktuğ N, Ünal OÜ, Şencan O, Erpolat Ö, Saip P, Kılıçkap S, Selçuk Seber SO, Paydaş S, Sarıhan S, Kömürcü Ş, Demirkasımoğlu T, Korkmaz T, Yetişyiğit T, Yavuzşen T, Evrensel T, Akman T, Abacıoğlu U, Kefeli U, Egeli Ü, Elgin Y, **Baran Y**, Bulut Z (Alphabetical order). The correlates of benefit from neoadjuvant chemotherapy before surgery in non-small-cell lung cancer: a metaregression analysis. *World Journal of Surgical Oncology*, **2012**; 10(1): 161-167.

47. Kozanoğlu İ*, **Baran Y***. Hematoloji laboratuvarında moleküler tanı yöntemlerinin kullanılması The use of molecular diagnostic methods in hematology laboratory. *Turkiye Klinikleri J Hem Onc-Special Topics*, **2012**; 5(4): 87-93.

2013

48. Gokbulut AA, Yardım MK, Iskender G, **Baran Y***. Novel Agents Targeting Bioactive Sphingolipids for the Treatment of Cancer. *Current Medicinal Chemistry*, **2013**; 20: 108-122.

49. Yandım MK, Apohan E, **Baran Y***. Therapeutic Potential of Targeting Ceramide/Glucosylceramide Pathway in Cancer. *Cancer Chemotherapy and Pharmacology*, **2013**; 71(1): 13-20.
50. Kozanoglu I, Yandim MK, Cincin ZB, Ozdogu H, Cakmakoglu B, **Baran Y***. New indication for therapeutic potential of an old well-known drug (propranolol) for multiple myeloma. *Journal of Cancer Research and Clinical Oncology*. **2013**; 139(2): 327-335.
51. Kaymaz BT, Selvi N, Adan Gokbulut A, Aktan Ç, Gündüz C, Saydam G, Şahin F, Çetintaş VB, **Baran Y**, Kosova B*. Suppression of STAT5A and STAT5B Chronic Myeloid Leukemia Cells via siRNA and Antisense-Oligonucleotide Applications with the Induction of Apoptosis. *American Journal of Blood Research*, **2013**; 3(1): 58-70.
52. **Baran Y***, Ceylan C, Camgoz A. The roles of macromolecules in imatinib resistance of chronic myeloid leukemia cells by Fourier transform infrared spectroscopy. *Biomedicine and Pharmacotherapy*, **2013**; 67: 221-227.
53. Senarisoy M, Canturk P, Zencir S, **Baran Y**, Topcu Z*. Gossypol interferes with both type I and type II topoisomerases activities without generating strand breaks. *Cell Biochemistry and Biophysics*, **2013**; 66(1): 199-204.
54. Turan T, Sanlı-Mohamed G*, **Baran Y***. Changes in Protein Profiles of Multiple Myeloma Cells in Response to Bortezomib. *Leukemia and Lymphoma*, **2013**; 54(5): 1061-1068.
55. Camgoz A, Gencer EB, Ural AU, **Baran Y***. Mechanisms responsible for nilotinib resistance in human chronic myeloid leukemia cells and reversal of resistance. *Leukemia and Lymphoma*, **2013**; 54(6): 1279-1287.
56. Sunay O, Can G, Cakir Z, Denek Z, Kozanoğlu I, Erdil G, Mustafa M, **Baran Y***. Autologous Rabbit Adipose Tissue Derived Mesenchymal Stem Cells For The Treatment Of Bone Injuries With Distraction Osteogenesis. *Cytotherapy*, **2013**; 15(6): 690-702.
57. Firatligil B, Avci CB, **Baran Y***. mir-17 in Imatinib Resistance and Response to Tryosine Kinase Inhibitors in Chronic Myeloid Leukemia Cells. *J. BUON*, **2013**; 18(2):437-441.
58. Gokbulut AA, Apohan E, **Baran Y***. Resveratrol and quercetin induced apoptosis of human 232B4 chronic lymphocytic leukemia cells by activation of caspase-3 and cell cycle arrest. *Hematology*, **2013**; 18(3):144-50.
59. Bozkurt S*, Özkan T, Özmen F, **Baran Y**, Sunguroğlu A, Kansu E. The roles of epigenetic modifications of proapoptotic BID and BIM genes in imatinib-resistant chronic myeloid leukemia cells. *Hematology*, **2013**, 18(4): 217-223.

60. Kiper HD, Tezcanli B, Gokbulut AA, Selvi N, Avci CB, Kosova BK, Iskender G, Yandım MK, Gunduz C, Sahin F, **Baran Y***, Saydam G. STAT pathway in the regulation of zoledronic acid-induced apoptosis in chronic myeloid leukemia cells. *Biomedicine and Pharmacotherapy*, **2013**; 67(6):527-532.
61. Can G, Akpınar B, **Baran Y**, Zhivotovsky B, Olsson M*. 5-Fluorouracil signaling through a calcium-calmodulin-dependent pathway is required for p53 activation and apoptosis in colon carcinoma cells. *Oncogene*, **2013**; 32(38):4529-4538.
62. Comert M, **Baran Y***, Saydam G. Changes in molecular biology of Chronic Myeloid Leukemia in Tyrosine Kinase Inhibitor era. *American Journal of Blood Research*, **2013**; (3):191-200.
63. Yılmaz AF, Saydam G, Sahin F, **Baran Y***. Granulocytic Sarcoma: A Systematic Review. *American Journal of Blood Research* **2013**;3(4):265-270.

2014

64. Ömür Ö*, **Baran Y**, Oral A, Ceylan Y. Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography For Extranodal Staging Of Non-Hodgkin Lymphoma And Hodgkin Disease. *Diagnostic and Interventional Radiology* **2014**;0(2):185-192.
65. Avci CB, **Baran Y***. Micro RNAs in Personalized medicine. *Methods in Molecular Biology; miRNomics: MicroRNA Biology and Computational Analysis*, Humana Press, **2014**, 1107:311-25
66. Aydemir LY, Adan Gokbulut A, **Baran Y**, Yemenicioglu A*. Bioactive, functional and edible film making properties of different protein isolates from Turkish hazelnut (*Corylus avellana* L.) meal obtained from oil extraction. *Food Hydrocolloids*, **2014**; 36:130-142.
67. Solmaz S, Gokbulut AA, Cincin B, Ozdogu H, Boga C, Cakmakoglu B, Kozanoglu I, **Baran Y***. Therapeutic Potential of Apigenin, a Plant Flavonoid, for Imatinib-Sensitive and Resistant Chronic Myeloid Leukemia Cells. *Nutrition and Cancer; An International Journal*, **2014**; 66(4): 599-612.
68. Celikkanat D, **Baran Y***. Comparative development of knowledge-based bioeconomy in the European Union and Turkey. *Critical Reviews in Biotechnology*, **2014**, 34(3): 269-280.
69. Omur O, **Baran Y***. An Update on Molecular Biology of Thyroid Cancers. *Critical Reviews in Oncology/Hematology*, **2014**; 90(3): 233-252.

70. Cincin ZB, Unlu M, Kiran B, Bireller ES, **Baran Y***, Cakmakoglu B*. Molecular Mechanisms of Quercitrin-Induced Apoptosis in Non Small Cell Lung Cancer Cells. Archives of Medical Research, **2014**; 45(6): 445-454.

71. Kiraz Y, Unlu M, Kartal Yandim M, **Baran Y***. Molecular Biology of Stem Cells. Hematolog, **2014**: 4(2); 255-265.

72. Unlu M, Kiraz Y, Kacı FN, Baran Y*. Multidrug Resistance in Chronic Myeloid Leukemia. Turkish Journal of Biology, 2014;38(6):806-816.

73. Demirer T, Baran Y, Camcı, C, Olgun N, Ozcelik T, Ozet A, Ozkok S, Solak M, Zulfikar B, Gultekin M. Ulusal Kanser Politikaları Çalıştayı, Türkiye Bilimler Akademisi, Kanser Çalışma Grubu.

2015

74. Cincin ZB, Unlu M, Kiran B, Bireller ES, **Baran Y***, Cakmakoglu B*. Apoptotic Effects of Quercitrin in DLD-1 Colon Cancer Cell Lines. Pathology and Oncology Research, **2015**: 21; 333–338.

75. Tufekçi O, Yandim MK, Oren H, Irken G, **Baran Y***. Targeting FOXM1 Transcription Factor In T-Cell Acute Lymphoblastic Leukemia. Leukemia Research, **2015**: 39(3); 342-347.

76. **Baran Y***. Kanserde İlaç Dirençliliği. Günce, Türkiye Bilimler Akademisi Dergisi, **2015**; 48: 67-70.

77. Gokbulut AA, **Baran Y***. A Novel Natural Product, KL-21, Inhibits Proliferation and Induces Apoptosis in Chronic Lymphocytic Leukemia Cells. Turkish Journal of Hematology, **2015**; 32(2): 118-26.

78. Katgı A*, Sevindik OG, Gokbulut AA, Ozsan HG, Yuksel F, Solmaz SM, Alacacioglu I, Ozcan MA, Demirkan F, **Baran Y**, Piskin O. Nilotinib Does Not Alter the Secretory Functions of Carotid Artery Endothelial Cells in a Prothrombotic or Antithrombotic Fashion. Clinical and Applied Thrombosis/Hemostasis, **2015**; 21(7): 678-83.

79. Cincin ZB, Unlu M, Kiran B, Bireller ES, Kiraz Y, **Baran Y**, Cakmakoglu B*. Anti-proliferative, apoptotic and signal transduction effects of hesperidin in non-small cell lung cancer cells. Cellular Oncology, **2015**; 38(3): 195-204.

80. Mutlu P, Kiraz Y, Gündüz U, **BaranY***. An Update on Molecular Biology And Drug Resistance Mechanisms of Multiple Myeloma. Critical Reviews in Oncology/Hematology, **2015**; 96(3): 413-424.

81. Adan A, **Baran Y***. The Pleiotropic Effects of Fisetin and Hesperetin on Human Acute Promyelocytic Leukemia Cells Are Mediated through Apoptosis, Cell Cycle Arrest and Alterations in Signaling Networks. *Tumor Biology*, **2015**; 36(11): 8973-8984.

82. Kaymaz BT, Günel NS, Ceyhan M, Çetintaş VB, Özel B, Yandım MK, Kıpçak S, Aktan Ç, Gökbulut AA, Baran Y, Can BK. Revealing genome-wide mRNA and microRNA expression patterns in leukemic cells highlighted Bhsa-miR-2278 as a tumor suppressor for regain of chemotherapeutic imatinib response due to targeting STAT5A. *Tumor Biology*; **2015**; 36(10): 7915-7927.

83. Kartal Yandım M, Adan Gokbulut A, **Baran Y***. Molecular Mechanisms of Drug Resistance and its Reversal in Cancer. *Critical Reviews in Biotechnology*, **2015**; 36(4): 716-726.

2016

84. Nalbant A, Kiraz Y, **Baran Y***. T cells in Tumor Microenvironment. *Tumor Biology*, **2016**; 37(1): 39-45

85. Adan A, Alizada G, Kiraz Y, Nalbant A, **Baran Y***. Flow cytometry: Basic principles and applications. *Critical Reviews in Biotechnology*, **2016**; 14: 1-14.

86. Kiraz Y, Adan A, Kartal Yandım M, **Baran Y***. Major apoptotic mechanisms and genes involved in apoptosis. *Tumor Biology*, **2016**; 37(7): 8471-8476.

87. Yandım MK, Ceylan C, Elmas E, **Baran Y***. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib. *Tumor Biology*, **2016**; 37(2): 2365-2378.

88. Adan A, **Baran Y***. Fisetin and hesperetin induced apoptosis and cell cycle arrest in chronic myeloid leukemia cells accompanied by modulation of cellular signaling. *Tumor Biology*, **2016**; 37(5): 5781-5795.

89. Kiraz Y, Neergheen-Bhujun VS, Rummun N, **Baran Y***. Apoptotic Effects Of Non-Edible Parts Of *Punica Granatum* On Human Multiple Myeloma Cells. *Tumor Biology*, **2016**; 37(2): 1803-1815.

90. Adan A, Kiraz Y, **Baran Y***. Cell Proliferation And Cytotoxicity Assays. *Current Pharmaceutical Biotechnology*, **2016**; 17(14): 1213-1221.

2017

91. Işık S*, Karaman M, Adan A, Kıray M, Bağrıyanık HA, Sözmen ŞÇ, Kozanoğlu İ, Karaman Ö, **Baran Y**, Uzuner N. Intraperitoneal Mesenchymal Stem Cell Administration Ameliorates Allergic Rhinitis in the Murine Model. *European Archives of Oto-Rhino-Laryngology and Head*

& Neck, **2017**; 274, 197-207.

92. Apohan E*, Yilmaz U, Yilmaz O, Serindag A, Kucukbay H, Yesilada O, **Baran Y**. Synthesis, Cytotoxic and Antimicrobial Activities of Novel Cobalt and Zinc Complexes of Benzimidazole Derivatives. *Journal of Organometallic Chemistry*, **2017**; 828, 52-58.

93. Işık S*, Uzuner N, Karaman M, Karaman Ö, Kiray M, Kozanoğlu İ, Bağrıyanık HA, Arıkan-Ayyıldız Z, Kartal Yandım M, **Baran Y***. Potent effects of mesenchymal stem cells on murine model of bronchiolitis obliterans. *Iranian Journal of Allergy, Asthma and Immunology*, **2017**; 16(3), 205-218.

94. Amuk NG, Kurt G, **Baran Y***, Seyrantepe V, Kartal-Yandim M, Adan A, Sönmez MF. Effects of Cell-Mediated Osteoprotegerin Gene Transfer and Mesenchymal Stem Cell Applications on Orthodontically Induced Root Resorption of Rat Teeth, *European Journal of Orthodontics* **2017**; 39(3):235-242.

95. Ozer I, Tomak A, Zareie HM, **Baran Y**, Bulmus V*. Effect of Molecular Architecture on Cell Interactions and Stealth Properties of PEG. *Biomacromolecules*, **2017**;18(9): 2699-2710.

96. Işık S, Uzuner N, Karaman M, Karaman Ö, Kiray M, Kozanoğlu İ, Alper Bağrıyanık H, Arıkan-Ayyıldız Z, Kartal Yandım M, **Baran Y***. Effects of Intraperitoneal Injection of Allogeneic Bone Marrow-derived Mesenchymal Stem Cells on Bronchiolitis Obliterans in Mice Model. *Iran J Allergy Asthma Immunol*, **2017**; 16(3): 205-218.

97. Neergheen-Bhujun V, Awan AT, **Baran Y**, Bunnefeld N, Chan K, Dela Cruz TE, Egamberdieva D, Elsässer S, Johnson MV, Komai S, Konevega AL, Malone JH, Mason P, Nguon R, Piper R, Shrestha UB, Pešić M, Kagansky A*. Biodiversity, drug discovery, and the future of global health: Introducing the biodiversity to biomedicine consortium, a call to action. *Journal of Global Health*. **2017** Dec;7(2):

2018

98. Cincin ZB, Kiran B, **Baran Y**, Cakmakoglu B*. Hesperidin promotes programmed cell death by downregulation of nongenomic estrogen receptor signalling pathway in endometrial cancer cells. *Biomedicine & Pharmacotherapy*, **2018**; 103: 336-345.

99. Iplik ES, Ertugrul B, Kozanoglu I, **Baran Y**, Cakmakoglu B*. An answer to colon cancer treatment by mesenchymal stem cell originated from adipose tissue. *Iranian Journal of Basic Medical Sciences*, **2018**; 21 (5): 465.

100. **Baran Y***, Kiraz Y, Ulu GT. *Kanser Moleküler Biyolojisi*, Kısayol Yayıncılık, 586 sayfa kitap, **2018**.

101. Gül Amuk N*, Kurt G, Kartal Yandim M, Adan A, **Baran Y.** A minimally invasive transfer method of mesenchymal stem cells to the intact periodontal ligament of rat teeth: A preliminary study. Turkish Journal of Biology, **2018**; 42(5): 382-391.

2019

102. Cox S, Rousseau-Tsangaris M, Abou-Zeid N, Dalle S, Leurent P, Cutivet A, Le HH, Kotb S, Bogaert B, Gardette R, **Baran Y,** Holder JM, Lerner L, Blay JY, Cambrosio A, Tredan O, Denèfle P*. Precision medicine in oncology: Challenges, stakes and new paradigms. Bull Cancer. 2019 Feb;106(2):97-104.

103. Ulu GT, Kiraz Y, **Baran Y***. The Role of Polyunsaturated Fatty Acids in Cancer and Their Use in Cancer Treatment. Reviews in Clinical Medicine. 2019;6(3):84-90.